Shenji Liu

TL;DR: It is reported that p19Arf (p14ARF in human) stabilizes Slug to inhibit E‐cadherin in prostate cancer mouse models, demonstrating that ARF has dual tumor suppressive/oncogenic roles in cancers in a context‐dependent manner.

TL;DR: It is reported that Skp2 modulates JARID1B and H3K4me3 levels in vitro in cultured cells and in vivo in mouse models, and the findings reveal a novel network of SKP2- JARIDs1B, and targeting SKp2 and JARid1B may be a potential strategy for PCa control.

TL;DR: It is reported that EZH2 is post-transcriptionally regulated by SKP2 in vitro in cultured cells and in vivo in mouse models, and a concurrent elevation of Skp2 and Ezh2 was found in CRPC tumors of Pten/Trp53 mutant mice, and expression levels ofSKP2 and EZh2 were positively correlated in human PCa specimens.

TL;DR: The findings reveal for the first time an essential role of nMET association with SOX9/β-catenin in CRPC in vitro and in vivo, highlighting that nuclear RTK activate cell reprogramming to drive recurrence, and targeting nMET would be a new avenue to treat recurrent cancers.

TL;DR: The findings establish the importance of MET in prostate cancer progression but reveal potential limitations in the clinical use of MET inhibitors in late-stage prostate cancer.